Kura Oncology and Caspian Therapeutics Detail Development Strategy for Diabetes Drug KO-7246
Caspian Therapeutics, Inc. and Kura Oncology, Inc. (KURA) outlined the development strategy for KO-7246, an experimental oral drug for diabetes. The announcement follows preclinical research presented at a European diabetes conference showing the compound expanded insulin-producing beta cells and improved glucose control in animal models.
Kura launched Caspian in September 2026 backed by a 50 million USD funding round that included Eli Lilly and Company. Kura transferred the drug candidate and related intellectual property to Caspian while retaining roughly half ownership. KO-7246 works by inhibiting menin, a protein that acts as a natural restraint on beta cell growth, aimed at restoring the body's ability to produce insulin.
Caspian is currently conducting studies required to support an investigational new drug application and initiate a Phase 1 clinical trial in patients with Type 1 or Type 2 diabetes. The early-stage trial will focus on evaluating safety, drug exposure, and biological indicators of insulin production such as C-peptide levels.
Key points
- Caspian Therapeutics, Inc. and Kura Oncology, Inc. (KURA) outlined clinical development plans for diabetes candidate KO-7246.
- Preclinical research demonstrated that KO-7246 expanded insulin-producing beta cells and restored glucose control in animal models.
- Kura launched Caspian in September 2026 with 50 million USD in financing and retains approximately 50% ownership in the firm.
- IND-enabling development is underway to support a planned Phase 1 trial evaluating safety and insulin creation in diabetes patients.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is KO-7246?
KO-7246 is an experimental oral menin inhibitor designed to treat diabetes by expanding beta cells and restoring the body's insulin-producing capacity.
What is Kura Oncology's relationship to Caspian Therapeutics?
Kura Oncology, Inc. launched Caspian Therapeutics in September 2026, contributing the KO-7246 candidate while retaining roughly 50% ownership.
What are the next steps for KO-7246?
Caspian Therapeutics is completing IND-enabling work to prepare for a Phase 1 clinical trial evaluating safety and insulin production in diabetes patients.